Cancer cells harboring mutations in genes involved in homologous recombination (HR)‐mediated DNA repair such as BRCA1 and BRCA2 are exquisitely sensitive to poly(ADP‐ribose) polymerase (PARP) inhibitors (Bryant et al, 2005; Farmer et al, 2005). This evidence concerns the gene BRCA1 and cancer.